Navigation Links
Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions

NATICK, Mass., Feb. 15, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of two novel technologies to treat peripheral chronic total occlusions (CTOs).  These acquisitions add technology platforms that complement the Company's world-class portfolio of devices for lower extremity peripheral artery disease.  

Boston Scientific acquired a re-entry catheter in November 2010 from S.I. Therapies, Ltd., based in Israel.  The Company will also acquire an intraluminal CTO crossing device through its acquisition of Sunnyvale, CA-based ReVascular Therapeutics, Inc., which is expected to close this month.  Worldwide launches of these devices in approved markets are planned later this year.  

"Having used both devices, I am impressed with their simplicity and effectiveness," said Dierk Scheinert, M.D., Heart Center Leipzig, and Professor of Medicine at the University of Leipzig.  "Access to these technologies will greatly enhance therapeutic options and provide physicians with new, intuitive solutions for treating challenging CTOs."

A CTO, which represents a complete artery blockage, typically cannot be treated with standard endovascular devices such as guidewires and other catheter-based technologies.  CTO devices permit endovascular treatment in cases that otherwise might require a patient to undergo surgery or lower extremity amputation.  By offering both a re-entry and intraluminal crossing device, Boston Scientific will be well positioned to help physicians address the challenges of treating complex peripheral lesions.

"The purchase of these innovative CTO technologies demonstrates a continued commitment to expanding our peripheral interventions business," said Joe Fitzgerald, Senior Vice President and President of Boston Scientific's Endovascular Unit.  "Not only will they augment our products for treating patients with lower extremity peripheral artery disease, but they will strengthen our clinical relationships with customers by offering them additional ways to deliver patient care."

"These acquisitions demonstrate our continued strategic execution of realigning and strengthening our portfolio in areas with high-growth potential," said Ray Elliott, President and Chief Executive Officer of Boston Scientific.  "Our Priority Growth Initiatives include peripheral vascular disease, in which a significant number of patients remain undiagnosed or untreated.  Addressing these challenges through use of less-invasive devices could greatly improve the care these patients receive."  

Together, the transactions are expected to have an immaterial impact on GAAP and adjusted earnings in 2011 and 2012 and be accretive thereafter.  Transactional financial terms were not disclosed.  

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit:  

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding the market for peripheral vascular disease, impact of the acquisitions on financial performance, acquisition strategy, the timing and success of product launches and product performance.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; integration of acquired companies; closing of announced acquisitions and divestitures; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:

Erik Kopp508-650-8660 (office)Media RelationsBoston Scientific CorporationSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine
2. Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds
3. Boston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2010
4. Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System
5. Boston Scientific Responds to DOJ Civil Lawsuit
6. Boston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S.
7. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
8. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
9. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan
10. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results
11. Boston Scientific to Acquire Atritech
Post Your Comments:
(Date:12/1/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached its enrollment target of 400 ... trial of aldoxorubicin in patients with previously treated soft ... in Q1 2016. The Phase 3 trial is a randomized, ... from the FDA at 79 sites in ...
(Date:12/1/2015)... 1, 2015   Craneware, Inc ., the ... today announced the company will showcase a new ... ® solution at the American Society for ... . The new features are focused on simplifying ... and managing enterprise-wide pharmacy charges to ensure compliance ...
(Date:12/1/2015)... Germany , December 1, 2015 /PRNewswire/ ... leading global manufacturer of eye and gaze tracking solutions, ... SMI remote eye trackers as a component of its ... concussions, eye sight, and medical and performance issues in ... part of SMI,s mass-market-ready eye tracking platform, which is ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing ... Jar, a container patent that allows for easier packing and organizing of items into ... worth $90 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing ...
(Date:12/1/2015)... ... ... Tampa is the first health care provider in the region to offer the vBloc® ... a vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients ... 40 to 45 kg, or a BMI of at least 35 to 39.9 kg with ...
(Date:12/1/2015)... ... ... Dr. Paul Vitenas, one of the top cosmetic surgeons in Texas ... the Best Single Physician Practice in the nation. Dr. Vitenas and his practice were ... the industry publication. , Dr. Vitenas said he was very honored to receive ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... the 7th Annual 2015 Golden Bridge Business Awards under the New Products and ... zero capex web based sample management software that helps labs organize ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... facilities, radiographic technicians must mark the film for accurate interpretation by the radiologist. ... of. Fortunately, an inventor from Sacramento, Calif., has found a way to alleviate ...
Breaking Medicine News(10 mins):